维普中文期刊产品整合服务
935篇 您的检索式:作者名="de Boer J"
    题名 作者 年代 出处 被引量
1Efficacy of thioguanine treatment in inflammatory bowel disease: A systematic review显示文摘AIM To critically assess the available literature regarding the efficacy of thioguanine treatment in inflammatory bowel disease(IBD) patients, irrespective of the(hepato-) toxicity profile.METHODS A systematic literature search of the MEDLINE database using Pub Med was performed using the keywords 'thioguanine', '6-TG', 'thioguanine', 'inflammatory bowel disease', 'IBD', 'Crohn's disease', 'Ulcerative colitis' and 'effectiveness' in order to identify relevant articles published in English starting from 2000. Reference lists of the included articles were crosschecked for missing articles. Reviewed manuscripts concerning the effectiveness of thioguanine treatment in IBD were reviewed by the authors and the data were extracted. Data were subsequently analyzed with descriptive statistics. Due to the lack of standardized outcomes, a formal meta-analysis was not performed.RESULTS A total of 11 applicable studies were found that involved the effectiveness of thioguanine therapy in IBD. Eight studies were conducted in a prospectivemanner, in the remaining three studies, data was collected retrospectively. In total, 353 IBD-patients(225 patients with Crohn's disease, 119 with ulcerative colitis and nine with unclassified IBD) with prior azathioprine/mercaptopurine resistance and/or intolerance(n = 321) or de novo thioguanine administration(n = 32) were included for analysis, of which 228(65%) had clinical improvement on thioguanine therapy, based on standard IBD questionnaires, biochemical parameters or global physician assessments. Short-term results were based on 268 treatment years(median follow-up 9 mo, range 3-22 mo) with a median daily dose of 20 mg(range 10-80 mg). Discontinuation, mostly due to adverse events, was reported in 72 patients(20%). CONCLUSION The efficacy of thioguanine therapy in IBD patients intolerant to conventional thiopurine therapy is observed in 65%, with short term adverse events in 20% of patients.Berrie Meijer Chris JJ Mulder Godefridus J Peters Adriaan A van Bodegraven Nanne KH de Boer 2016World Journal of Gastroenterology2016,22,40:5
2On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprineor 6-mercaptopurine intolerant IBD patients显示文摘AIM: To determine the tolerability and safety profile of a low-dose maintenance therapy with 6-TG in azathioprine (AZA) or 6-mercaptopurine (6-MP) intolerant inflammatory bowel disease (IBD) patients over a treatment period of at least 1 year.METHODS: Database analysis.RESULTS: Twenty out of ninety-five (21%) patients discontinued 6-TG (mean dose 24.6 mg; mean 6-TGN level 540 pmol/8×108 RBC) within 1 year. Reasons for discontinuation were GI complaints (31%), malaise (15%)and hepatotoxicity (15%). Hematological events occurred in three patients, one discontinued treatment. In the 6-TG-tolerant group, 9% (7/75) could be classified as hepatotoxicity. An abdominal ultrasound was performed in 54% of patients, one patient had splenomegaly.CONCLUSION: The majority of AZA or 6-MP-intolerant IBD patients (79%) is able to tolerate maintenance treatment with 6-TG (dosages between 0.3 and 0.4 mg/kg per d). 6-TG may still be considered as an escape maintenance immunosuppressant in this difficult to treat group of patients, taking into account potential toxicity and efficacy of other alternatives. The recently reported hepatotoxicity is worrisome and 6-TG should therefore be administered only in prospective trials.Nanne KH de Boer Luc JJ Derijks Lennard PL Gilissen Daniel W Hommes Leopold GJB Engels Sybrand Y de Boer Gijsbertus den Hartog Piet M Hooymans Anja BU M(?)kelburg Barend D Westerveld Anton HJ Naber Chris JJ Mulder Dirk J de Jong 2005World Journal of Gastroenterology2005,11,35:4
3Limitation of myocardial infarct size after primary angioplasty:Is a higher patency the only mechanism?显示文摘OTTERVANGER J P LIEM A De BOER M J 1999Am Heart J1999,137,3:2
4幽门螺杆菌感染的治疗显示文摘Wink A de Boer Guido N J Tytgat 游晓萍 姚炜 2001英国医学杂志中文版2001,4,3:2
5Differentiation and molecular detection of Canadian necrotic strains of Potato virus Y显示文摘Xu H Nie J De Boer S H 2005Can J Plant Pathol2005,27,:1
6Do flame retar-dants threaten ocean life显示文摘De Boer J Wester P G Klammer H J C 1998Nature1998,394,6688:1
7Costimulatory molecules in human atherosclerotic plaques: an indication of antigen specific T lymphocyte activation显示文摘Onno J de Boer Floris Hirsch Allard C van der Wal Chris M van der Loos Pranab K Das Anton E Becker 1997Atherosclerosis1997,,2:1
8Coagulation disorders in septic shock 显示文摘Thijs L G de Boer J P de Groot M C 1993Intensive Care Med1993,19,1:1
9Reperfusion therapy in elderly patients with acute myocardial infarction: a randomized comparison of primary angioplasty and thrombolytic therapy 显示文摘de Boer M J Ottervanger J P vant Hof A W 2002J Am Coil Cardiol2002,39,11:1
10Protective efficacy Of Marek's disease virus(MDV)CVI-988 CEF65 clone against challenge infection with three very virulent MDV strains显示文摘de Boer G F Groenendal J E Boerrigter H M 1986Avian Dis1986,30,2:1
11Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide显示文摘Siderov J Prasad P De Boer R 2002Br J Cancer2002,86,1:1
12Monocyte chemoattractant protein 1 ,interleukin 8, and chronic airways inflammation in COPD 显示文摘De Boer WI Sont JK Van Schadewijk A Stolk J van Krieken JH Hiemstra PS 2000Journal of Pathol2000,190,5:1
13Comparison of ^99mTc-Sestamibi-^18 F-fluorodeoyglucose dual isotope simultaneous acquisition and rest-stress ^99m Tc-Sestamibi single photon emission computed tomography for the assessment of myocardial viability显示文摘De Boer J Shart RH Blanksma PK 2003Nucl Med Commun2003,24,3:1
14Analysis of ammonia-oxidizing bacteria of the 13 subdivision of the class Pro- teobacteria in coastal sand dunes by denaturing gradient gel electro- pboresis and sequencing of PCR-amplified 16S ribosomal DNA frag- ments 显示文摘KOWALCHUK G A STEPHEN J R DE BOER W 1997Appl Environ Microbiol1997,63,4:1
15The use of endothelial progenitor cells for prevascularized bone tissue engineering显示文摘Rouwkema J Westerweel P E de Boer J 2009Tissue Eng Part A2009,15,8:1
16Capturability-based analysis and control of legged locomotion, Part 2: Application to M2V2, a lower-body humanoid显示文摘Pratt J Koolen T de Boer T 2012International Journal of Robotics Research2012,31,10:1
17The prevalence of bother,acceptance,and need for help in men with erectile dysfunction显示文摘DE BOER B J BOTS M L NIJEHOLT A A 2005J Sex Med2005,2,3:1
18Formation of a near { 100 } (110) recrystallization texture in electrical steels 显示文摘Boer B de Wieting J 1997Scripta Materialia1997,37,6:1
19Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide 显示文摘Siderov J Prasad P De Boer R 2002Br J Cance2002,86,:1
20Determination of brominated flame retardants,with emphasis on poly brominated diphenyl ethers (PBDEs) in environmental and human samples-a review显示文摘Covaci A Vorspoels S de Boer J 2003Environment International2003,29,:1
返回顶部 每页显示:
共47页 首页 上一页 第1页 下一页 末页 /47 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费